Anti-tumor drug. This product is a non-specific drug for the cell cycle, but it has a more obvious effect on the S phase, increasing the number of cells in the G1 phase and reducing the number of cells in the S phase and G2M phase. Its mechanism of action is to inhibit the initial stage of protein synthesis, inhibit the activity of DNA polymerase α, lead to a decrease in DNA synthesis, and severely inhibit protein synthesis. This product also has the effects of inducing cell differentiation, increasing cAMP content, and inhibiting glycoprotein synthesis.

Not yet clear

Not yet clear

This product is an anti-anemia drug. Vitamin B12 participates in methyl conversion and folic acid metabolism in the body, and promotes the conversion of 5-methyltetrahydrofolate into tetrahydrofolate. When it is deficient, it leads to DNA synthesis disorders and affects the maturation of red blood cells. This product also promotes the conversion of methylmalonic acid into succinic acid and participates in the tricarboxylic acid cycle. This effect is related to the synthesis of nerve myelin lipids and the maintenance of the integrity of myelinated nerve fiber function. The nerve damage caused by vitamin B12 deficiency may be related to this.

This product is a compound of aminopyrine and sodium sulfite. It is easily soluble in water and has faster and stronger antipyretic and analgesic effects than aminopyrine.

It depletes the norepinephrine storage in the peripheral sympathetic nerve terminals, and also depletes the catecholamine and 5-hydroxytryptamine storage in the brain, heart and other organs. The blood pressure reduction is mainly peripheral, the peripheral vascular resistance is reduced, the heart rate is slowed down, and the cardiac output is reduced, thereby lowering the blood pressure.